Actionable news
All posts from Actionable news

Tekmira Pharmaceuticals: Arbutus Provides An Hbv Pipeline Update EXHIBIT 99.1

The following excerpt is from the company's SEC filing.

Arbutus Provides an HBV Pipeline Update

TKM-HBV Progressing to Phase II in HBV Infected Patients by Year-End

TKM-HBV Phase II S-Antigen Reduction Data Expected in 2016

Initiation of Proprietary Combination Studies in HBV Infected Patients Expected in 2017

Conference Call Scheduled for 7:30AM Pacific

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today issued an update on the company's HBV pipeline, including plans to progress lead pipeline candidate TKM-HBV into a multi-dose Phase II study in HBV infected patients by year-end.

TKM-HBV, Arbutus' RNAi product candidate for HBV, is progressing to a Phase II multi-dosing study in HBV infected patients based on results to date from a Phase I single ascending dose study. TKM-HBV, which comprises three RNAi triggers that target all HBV transcripts, has been shown in preclinical studies to reduce all viral antigen levels as well as cccDNA. TKM-HBV's design will target hepatitis B surface antigen (HBsAg) expression regardless of its source. The Phase I clinical trial is a randomized, single-blind, placebo-controlled study, involving single ascending doses of TKM-HBV. The study is assessing the safety, tolerability and pharmacokinetics of intravenous administration of two LNP formulations (third and fourth generation) of TKM-HBV in healthy adult subjects. In order to enable maximum TKM-HBV dose escalation, steroid premedication was added to the Phase I protocol. At this time, a maximum tolerated dose has not yet been reached and evaluation of higher doses is under consideration.

TKM-HBV Phase II Study

Pending confirmation from the relevant regulatory authorities, the Phase II study will evaluate two dose levels of TKM-HBV administered as three monthly doses in chronic HBV infected patients who are on stable background nucleot(s)ide analog therapy. In the proposed protocol, eight subjects will be enrolled in each of the dose cohorts with six subjects receiving TKM-HBV, and two receiving placebo. Dosing in this study is expected to begin by year-end. HBsAg reduction results are expected to be reported in 2016. The TKM-HBV product candidate that will be studied in Phase II will be referred to as ARB-1467.

Status update on other HBV pipeline programs

Arbutus believes that direct-acting antiviral drugs such as TKM-HBV, cccDNA formation inhibitors and core protein/capsid assembly inhibitors represent the most important approaches with the highest probability of contributing to a cure. As a result, Arbutus has prioritized and accelerated development of its direct acting antiviral product candidates including the company's cccDNA formation inhibitors and core protein/capsid assembly inhibitors.

cccDNA formation inhibitors.

Arbutus has made significant progress with its discovery of potent and unique small molecule cccDNA formation inhibitors, directly targeting this unique viral reservoir. As presented at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses earlier this month, Arbutus' cccDNA formation inhibitors demonstrate synergy with approved nucleot(s)ide analogs in preclinical models, which supports the potential for added benefit when combining these agents in HBV infected patients. Arbutus expects to file an IND (or equivalent filing) for a cccDNA formation inhibitor in 2H16, with a plan to include the molecule in combination studies in 2017.

Core protein/capsid assembly inhibitors.

HBV core protein, or capsid, is required for viral replication and core protein may have additional roles in cccDNA function. Current nucleot(s)side analog therapy significantly reduces serum HBV DNA levels but HBV continues to replicate in the liver, thereby enabling the infection to persist and progress. Effective therapy for patients requires combinations consisting of new agents that will more effectively block viral replication. Arbutus has identified potent and unique HBV core...